BioSpace - Elan Pharmaceuticals News, Search Jobs, Events

Industry

Segment

Elan Pharmaceuticals (ELN) Lab Liquidation Auctions -- South San Francisco Closure; to be Hosted by BioSurplus on Its Secure Online Auction Platform 1/9/2013 9:42:25 AM More...

Elan Pharmaceuticals (ELN) Hoping Alzheimer's Drug Will "Transform" Firm 5/25/2012 7:55:40 AM More...

Elan Pharmaceuticals (ELN) to Present at the Leerink Swann 2012 Global Healthcare Conference 2/2/2012 6:19:42 AM More...

Intellect Neurosciences, Inc. Files Appeal in Europe in Response to Opposition Proceedings Instituted by Elan Pharmaceuticals (ELN) and Wyeth (WYE)/Pfizer Inc. (PFE) 12/15/2011 10:55:05 AM More...

Elan Pharmaceuticals (ELN) Presents 7th Annual Danville Concours d'Elegance Weekend 8/30/2011 5:50:01 AM More...

Elan Pharmaceuticals (ELN) Pays Transition Therapeutics Inc. (TTH.TO) $9M in Amended Deal for Phase II Alzheimer Candidate; Transition Eligible for $11 Million More 12/27/2010 7:40:40 AM More...

Lundbeck Inc. (formerly Ovation Pharmaceuticals) CFO: Elan Pharmaceuticals (ELN) Not an Acquisition Option Now 5/13/2009 11:26:23 AM More...

Elan Corporation PLC (ELN)'s Tysabri May Reverse MS Damage, Shares Up 4/29/2009 7:28:54 AM More...

Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company an Option to License Certain Alzheimer's Patents and Patent Applications 10/8/2008 8:57:49 PM More...

Biogen Idec, Inc. (Massachusetts) (BIIB) And Elan Pharmaceuticals (ELN) Announce That FDA Will Extend Regulatory Review Period For The Reintroduction Of TYSABRI(R) For Multiple Sclerosis 3/22/2006 10:37:02 AM More...